Diabetes mellitus imposes a substantial burden on cardiovascular health, with individuals living with the condition facing a two- to four-fold higher risk of developing heart disease, stroke, and peripheral artery disease compared to those without diabetes. Cardiovascular disease is the leading cause of morbidity and mortality in this population, accounting for roughly two-thirds of all deaths among people with type 2 diabetes. The convergence of chronic hyperglycemia, insulin resistance, and concurrent metabolic disturbances accelerates the development of atherosclerosis, heart failure, and arrhythmias. Because the onset of cardiovascular complications often occurs silently, early identification of at-risk individuals is essential for preventing catastrophic events such as myocardial infarction or stroke.

Biomarkers have emerged as indispensable tools for stratifying cardiovascular risk among patients with diabetes. A biomarker is a biological molecule found in blood, urine, or other tissues that signals normal or abnormal processes, or the presence of disease. In the clinical context, biomarkers can indicate the severity of a disease state, predict future adverse events, or monitor response to therapy. When applied to diabetes-associated cardiovascular disease, biomarkers allow clinicians to move beyond traditional risk factors such as age, hypertension, and smoking. They provide a more granular view of underlying pathophysiologic processes, including inflammation, endothelial dysfunction, oxidative stress, and metabolic derangement. This deeper insight enables tailored prevention strategies and more aggressive intervention when warranted.

The 2023 American Diabetes Association Standards of Medical Care in Diabetes emphasizes that a comprehensive approach to cardiovascular risk assessment must incorporate not only standard clinical factors but also relevant biomarkers. The incorporation of biomarkers into risk prediction models has been shown to improve discrimination and reclassification of patients, particularly those with intermediate risk. As research continues to refine these markers, the integration of biomarker testing into routine diabetes care represents a meaningful advance in precision medicine. This article examines both established and emerging biomarkers that aid in assessing the likelihood of cardiovascular events in people with diabetes, discusses their clinical applications, and highlights future directions for improving risk stratification.

Pathophysiology of Cardiovascular Risk in Diabetes

To understand why biomarkers are so valuable, it is helpful to appreciate the complex biological interplay between diabetes and cardiovascular disease. Chronic hyperglycemia, the hallmark of diabetes, triggers a cascade of damaging effects on the vasculature. High glucose levels promote the formation of advanced glycation end-products, which bind to receptors on endothelial cells and incite inflammatory signaling pathways. This process impairs the normal function of the lining of blood vessels, leading to reduced nitric oxide bioavailability, increased vasoconstriction, and a pro-thrombotic state.

Insulin resistance, common in type 2 diabetes, further compounds the problem. In adipose tissue and muscle, resistance to insulin action reduces glucose uptake and promotes lipolysis, resulting in elevated free fatty acids. These fatty acids generate reactive oxygen species and stimulate pro-inflammatory cytokine release, contributing to systemic low-grade inflammation. The combination of hyperglycemia, insulin resistance, and dyslipidemia — defined by elevated triglycerides, small dense low-density lipoprotein particles, and low high-density lipoprotein — drives the development of atherosclerosis, which is the primary substrate for most cardiovascular events.

Endothelial dysfunction is often considered an early event in this cascade, and it is closely linked to both glycemic control and inflammatory status. As endothelial integrity degrades, the vessel wall becomes more permeable to circulating lipids and immune cells. Foam cells form, fatty streaks develop, and eventually a complex atherosclerotic plaque emerges. Plaque rupture or erosion then precipitates acute coronary syndromes or stroke. Additionally, diabetes directly affects the myocardium, promoting fibrosis, diastolic dysfunction, and an increased propensity for heart failure, even in the absence of coronary artery disease.

Because these pathophysiological processes can be measured, biomarkers such as high-sensitivity C-reactive protein (hs-CRP), urinary albumin excretion, and certain lipid subfractions provide real-time windows into the disease activity. By quantifying the degree of inflammation, endothelial injury, or metabolic stress, biomarkers enable a level of precision that clinical algorithms alone cannot achieve.

Traditional Biomarkers and Their Clinical Utility

Glycated Hemoglobin (HbA1c)

Glycated hemoglobin, or HbA1c, is perhaps the most widely recognized biomarker in diabetes care. It reflects the average blood glucose concentration over the preceding two to three months and serves as the primary measure of glycemic control. Numerous epidemiologic studies have established a robust, continuous relationship between HbA1c levels and cardiovascular outcomes. The landmark United Kingdom Prospective Diabetes Study (UKPDS) demonstrated that each 1% reduction in HbA1c in patients with newly diagnosed type 2 diabetes was associated with a 14% reduction in myocardial infarction and a 12% reduction in stroke over 10 years of follow-up. Similarly, the Diabetes Control and Complications Trial (DCCT) in type 1 diabetes showed that intensive glycemic control lowered the risk of cardiovascular events over the long term.

Current guidelines from the American Diabetes Association recommend a target HbA1c of less than 7% for most nonpregnant adults with diabetes, although targets are often individualized based on age, life expectancy, comorbid conditions, and risk of hypoglycemia. As a biomarker for cardiovascular risk, HbA1c provides both a measure of cumulative glucose exposure and a modifiable target for intervention. However, it does have limitations: it can be influenced by conditions affecting red blood cell turnover (e.g., anemia, chronic kidney disease, hemolysis) and does not capture glycemic variability, which may independently contribute to cardiovascular damage.

Fasting and Postprandial Blood Glucose

Fasting plasma glucose is routinely measured and remains a diagnostic criterion for diabetes. Elevated fasting glucose levels reflect impaired hepatic glucose regulation and peripheral insulin resistance. Observational data suggest that fasting glucose levels above 100 mg/dL are associated with increased cardiovascular risk, even within the prediabetic range. Postprandial hyperglycemia is thought to be particularly damaging due to acute oxidative stress and endothelial dysfunction produced by glucose spikes after meals. Some evidence indicates that postprandial glucose may be a stronger predictor of cardiovascular disease than fasting glucose alone, although consensus on routine use for risk prediction is lacking. Nonetheless, both fasting and post-meal glucose assessments contribute to the overall risk picture.

High-Sensitivity C-Reactive Protein (hs-CRP)

Inflammation lies at the heart of atherosclerosis, and no inflammatory biomarker has been studied as extensively in cardiovascular risk prediction as high-sensitivity C-reactive protein. Produced by the liver in response to interleukin-6 and other pro-inflammatory cytokines, CRP levels rise in the setting of systemic inflammation. In individuals with diabetes, who often have an underlying inflammatory milieu, hs-CRP adds independent prognostic information beyond that provided by traditional risk factors. The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) demonstrated that patients with elevated hs-CRP levels (≥2 mg/L) but normal LDL cholesterol derived significant benefit from statin therapy, including those with diabetes. Moreover, data from the Emerging Risk Factors Collaboration indicate that hs-CRP is associated with cardiovascular events in a log-linear fashion, with no threshold effect — meaning that even modest elevations confer risk.

Current international guidelines recommend measurement of hs-CRP as a part of advanced risk assessment in intermediate-risk individuals. In diabetic patients, an hs-CRP level greater than 2 mg/L suggests increased cardiovascular risk and may prompt more aggressive lipid-lowering or lifestyle interventions. It is important to note that acute infections, trauma, or inflammatory conditions can transiently raise CRP levels, so readings should be taken when the patient is clinically stable.

Lipid Profile (LDL, HDL, Triglycerides)

Dyslipidemia in diabetes is characterized by elevated triglycerides, reduced high-density lipoprotein cholesterol (HDL-C), and a predominance of small, dense low-density lipoprotein particles. A standard lipid panel, which includes total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides, remains a cornerstone of cardiovascular risk assessment. Elevated LDL cholesterol is the primary target of lipid-lowering therapy, with statins as first-line agents. However, the atherogenic dyslipidemia seen in diabetes means that non-HDL cholesterol (total cholesterol minus HDL) and apolipoprotein B may better capture risk than LDL alone, because they include atherogenic remnant lipoproteins.

Despite the widespread use of statins, the residual risk of cardiovascular events in diabetic populations remains high, highlighting the need for additional biomarkers. For instance, lipoprotein(a) is an LDL-like particle that is highly pro-atherogenic and thrombogenic, and elevated levels may be particularly relevant in individuals with diabetes. However, lipoprotein(a) is not measured as part of a standard lipid profile and is considered an emerging marker for specific populations.

Urinary Albumin Excretion (Microalbuminuria)

The presence of small amounts of albumin in the urine — termed microalbuminuria — is a well-established biomarker for diabetic kidney disease and a powerful predictor of cardiovascular events. Microalbuminuria reflects generalized endothelial dysfunction and increased vascular permeability, not only in the glomerulus but also in the coronary and peripheral vasculature. Studies show that the risk of cardiovascular morbidity and mortality increases progressively with increasing urinary albumin excretion, even at levels well below the threshold for microalbuminuria. The Heart Outcomes Prevention Evaluation (HOPE) study found that the presence of microalbuminuria in patients with diabetes raised the relative risk of major cardiovascular events by approximately 1.8-fold, independent of other risk factors.

Current guidelines recommend annual screening for albuminuria in all patients with type 1 diabetes (duration ≥5 years) and type 2 diabetes (starting at diagnosis). Interventions that reduce albuminuria, such as renin-angiotensin-aldosterone system inhibitors (ACE inhibitors or ARBs), are associated with reduced cardiovascular event rates, making this biomarker not only a risk predictor but also a therapeutic target.

Emerging Biomarkers and Advanced Risk Stratification

Lipoprotein(a) [Lp(a)]

Lipoprotein(a) is a genetically determined lipoprotein that resembles LDL but contains an additional protein called apolipoprotein(a). Elevated Lp(a) levels are a causal risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis. In patients with diabetes, the relationship between Lp(a) and cardiovascular risk appears complex, as some studies report that the risk associated with high Lp(a) is attenuated in the presence of poor glycemic control. Nevertheless, measurement of Lp(a) is recommended by several expert panels for individuals with a family history of premature cardiovascular disease or for those who experience recurrent events despite optimal traditional risk factor management. Emerging therapies that lower Lp(a) are in development and may offer additional risk reduction for diabetic patients with high levels.

Apolipoprotein B (apoB) and Non-HDL Cholesterol

Apolipoprotein B is the main protein component of all atherogenic lipoproteins, including LDL, very low-density lipoprotein (VLDL), and lipoprotein(a). In patients with diabetes, the concentration of apoB particles often correlates more closely with cardiovascular risk than LDL cholesterol alone. The American Diabetes Association suggests that non-HDL cholesterol (total cholesterol minus HDL) is a suitable surrogate for apoB and can be used for risk assessment, especially when triglycerides are elevated. Measuring apoB directly is increasingly available and may help refine risk estimation in individuals with well-controlled LDL but high triglyceride levels.

Inflammatory Cytokines and Other Novel Markers

Beyond hs-CRP, several other inflammatory biomarkers have been investigated for their ability to predict cardiovascular events in diabetes. Interleukin-6 (IL-6) is a key upstream inflammatory cytokine, and elevated levels have been associated with increased risk of coronary heart disease. Myeloperoxidase, matrix metalloproteinases, and growth differentiation factor 15 (GDF-15) are gaining attention as potential markers of plaque instability and myocardial stress. GDF-15, in particular, has shown strong associations with heart failure and mortality outcomes in diabetic populations and may help identify individuals at risk for heart failure events. Additionally, microRNAs — small non-coding RNAs that regulate gene expression — are being explored as circulating biomarkers that reflect vascular damage and metabolic dysregulation. Although many of these markers are not yet ready for routine clinical use, they highlight the expanding landscape of biological information that can be harnessed for risk assessment.

Genetic and Epigenetic Markers

Diabetes and cardiovascular disease both have substantial heritable components. Polygenic risk scores for coronary artery disease have been developed that aggregate the effect of many common genetic variants into a single score. When applied to individuals with diabetes, these scores can identify those at markedly elevated risk, prompting earlier and more intensive preventive therapy. However, the clinical implementation of polygenic risk scores remains limited due to complexities in interpretation, potential for anxiety, and lack of established thresholds for action. Epigenetic markers, such as DNA methylation patterns influenced by glycemic memory, are also under investigation as predictors of long-term vascular complications.

Integrating Biomarkers into Comprehensive Risk Assessment Models

Individual biomarkers are most powerful when combined into multivariable risk prediction models. The UKPDS risk engine is one of the most widely used calculators that incorporates HbA1c, diabetes duration, atrial fibrillation, and other clinical factors to estimate 10-year risk of coronary heart disease and stroke. The 2018 American College of Cardiology/Atherosclerosis Cardiovascular Disease (ASCVD) Risk Estimator Plus includes diabetes as a risk-enhancing factor but does not directly incorporate biomarkers like hs-CRP or albuminuria. Adding these biomarkers to conventional risk models has been shown to improve discrimination (C-statistic) and reclassification of patients into appropriate risk categories, especially among those with borderline or intermediate risk.

Clinical decision-making often involves interpreting multiple biomarker results simultaneously. For example, a patient with type 2 diabetes who has an HbA1c of 8.5%, hs-CRP of 3.5 mg/L, microalbuminuria (urine albumin-to-creatinine ratio of 60 mg/g), and LDL of 120 mg/dL would be considered very high risk, warranting a high-intensity statin, maximization of glucose-lowering therapy (including agents with cardiovascular benefit like GLP-1 receptor agonists or SGLT2 inhibitors), and possibly addition of an ACE inhibitor or ARB. In contrast, a patient with an HbA1c of 6.8%, hs-CRP of 1.0 mg/L, and normal albumin excretion may have relatively lower risk and could be managed more conservatively, though still with standard preventive care.

Clinical Management Guided by Biomarker Assessment

The ultimate goal of biomarker-based risk assessment is to guide interventions that reduce the probability of cardiovascular events. In addition to stringent glycemic control, lipid management is paramount. Statins are the foundation of lipid-lowering therapy and are recommended for nearly all adults with diabetes aged 40–75 years, regardless of baseline LDL, due to the high baseline risk. In patients with established cardiovascular disease or elevated hs-CRP, adding ezetimibe or a PCSK9 inhibitor may be considered for further LDL reduction.

Glucose-lowering medications with proven cardiovascular benefit — namely, GLP-1 receptor agonists (e.g., liraglutide, semaglutide) and SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) — are recommended by international guidelines for patients with type 2 diabetes and established cardiovascular disease or high risk. These agents not only improve glycemic control but also reduce major adverse cardiovascular events (MACE) and, in the case of SGLT2 inhibitors, decrease hospitalization for heart failure. The mechanism for these benefits extends beyond glucose lowering to include anti-inflammatory, weight-reducing, and hemodynamic effects.

Anti-inflammatory therapy is a more recent consideration. The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) showed that targeting inflammation with canakinumab (an IL-1β inhibitor) reduced cardiovascular events in high-risk patients, including those with diabetes, independent of lipid lowering. Although canakinumab is not widely used due to cost and infection risk, the trial validated inflammation as a therapeutic target and spurred interest in older, inexpensive anti-inflammatory agents such as colchicine, which has shown benefit in the COLCOT and LoDoCo2 trials.

Lifestyle interventions remain the cornerstone of diabetes management and cardiovascular risk reduction. Weight loss, increased physical activity, dietary modifications (particularly a Mediterranean diet), and smoking cessation all lower inflammatory markers, improve lipid profiles, and reduce albuminuria. Patients identified as high-risk by biomarker assessment derive the greatest absolute benefit from these lifestyle changes, as well as from pharmacotherapy.

Future Directions and Personalized Medicine

The field of biomarker research is rapidly advancing, fueled by technological progress in genomics, proteomics, metabolomics, and lipidomics. Multi-omics approaches that integrate data from DNA, RNA, proteins, and metabolites hold promise for constructing highly personalized risk profiles. Wearable devices that continuously monitor glucose, physical activity, and heart rate variability may also provide time-sensitive physiological data that complement traditional biomarkers. Efforts are underway to develop machine learning algorithms that can synthesize these diverse data streams into actionable risk predictions for individual patients.

At the same time, there is a need for more standardized laboratory assays, reference ranges, and clinical decision limits for many emerging biomarkers. Large prospective studies are required to validate whether incorporating novel markers leads to improved patient outcomes in randomized controlled trials. Ongoing initiatives such as the National Institutes of Health's All of Us Research Program and large-scale diabetes cohorts will likely accelerate discovery and translation.

Another frontier is the role of biomarkers in guiding therapy de-escalation or escalation. For instance, patients with low inflammation (e.g., hs-CRP below 1 mg/L) might not require as aggressive intervention, whereas those with persistently elevated inflammatory markers despite optimal medical therapy may be candidates for novel anti-inflammatory agents. Tying treatment decisions directly to biomarker profiles will move the field closer to truly personalized diabetes care.

Conclusion

Biomarkers are not merely academic curiosities; they are actionable indicators that refine the estimation of cardiovascular risk in individuals with diabetes and guide therapeutic strategies to mitigate that risk. Established markers such as HbA1c, hs-CRP, lipid subfractions, and urinary albumin excretion already form part of routine clinical assessment and have proven value. Emerging markers including lipoprotein(a), apolipoprotein B, inflammatory cytokines, and genetic scores offer additional layers of precision. As the evidence base grows and technologies mature, the integration of multiple biomarkers will likely become standard practice, enabling earlier detection of high-risk individuals and more effective prevention of heart attacks, strokes, and heart failure. Clinicians should stay abreast of evolving guidelines and incorporate biomarker assessment into their decision-making to deliver the best possible outcomes for patients living with diabetes.

For further reading, consult the American Diabetes Association Standards of Medical Care in Diabetes, the European Society of Cardiology guidelines on cardiovascular disease prevention, and the National Heart, Lung, and Blood Institute resources on atherosclerosis.